Development and description of GETT: a Genetic testing Evidence Tracking Tool
Authors:
- François RousseauFRFrançois Rousseau
- Carmen LindsayCLCarmen Lindsay
- Marc CharlandMCMarc Charland
- Jean BergeronJBJean Bergeron
- Ingeborg BlancquaertIBIngeborg Blancquaert
- Grant A. MitchellGMGrant A. Mitchell
- Luc OlignyLOLuc Oligny
- Mario PazzagliMPMario Pazzagli
- 27 July 2010
- journal article
- research article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 48 (10) , 1397-1407
Abstract
Background: The completion of the Human Genome Project has increased the pace of discovery of genetic markers for disease. Despite tremendous efforts in fundamental research, clinical applications still lag behind expectations, partly due to the lack of effective tools to systematically search for and summarize published data relative to the clinical assessment of new diagnostic molecular tests. Methods: Through a collaborative process using published tools and an expert panel, we developed a detailed checklist of the evidence that needs to be collected or produced to evaluate the potential usefulness of a new molecular diagnostic test. This tool is called GETT, for Genetic testing Evidence Tracking Tool. Results: GETT allows 1) researchers to summarize the current evidence and to identify knowledge gaps for further research and; 2) stakeholders to collect data related to a given molecular test and improve their decision-making process. GETT comprises 72 clearly defined items/questions, grouped into 10 categories and 26 sub-themes, including an overview of disease epidemiology and genetics, the available diagnostic tools, and their analytical and clinical performances, availability of quality control programs, laboratory and clinical best practice guidelines, clinical utility, and impact on health care and psycho-social, ethical and legal implications. It also includes a summary of the evidence available and attempts to prioritise knowledge gaps related to the testing. We also compare GETT to other existing frameworks. Conclusions: This systematic evidence-based tracking tool, which is more detailed than existing frameworks and provides clear definition for each item, will help streamline collection of the available evidence to appraise the potential for clinical application of new molecular diagnostic tests and prioritize research to produce the evidence-base relative to the clinical implementation of molecular diagnostic tests. Clin Chem Lab Med 2010;48:1397–407.Keywords
This publication has 28 references indexed in Scilit:
- The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working GroupGenetics in Medicine, 2009
- DNA-based Genetic Testing Is Rising Steeply in a National Health Care System with Open Access to Services: A Survey of Genetic Test Use in Germany, 1996–2002Genetic Testing, 2005
- Evidence-Based Guidelines in Laboratory Medicine: Principles and MethodsClinical Chemistry, 2004
- Welcome to the Genomic EraNew England Journal of Medicine, 2003
- Categorizing genetic tests to identify their ethical, legal, and social implicationsAmerican Journal of Medical Genetics, 2001
- Oversight of Genetic Testing: An UpdateThe Journal of Molecular Diagnostics, 2001
- Laboratory standards and guidelines for population-based cystic fibrosis carrier screeningGenetics in Medicine, 2001
- Medical and Societal Consequences of the Human Genome ProjectNew England Journal of Medicine, 1999
- A Practical Guide for the Validation of Genetic TestsGenetic Testing, 1999
- Use of methodological standards in diagnostic test research. Getting better but still not goodJAMA, 1995